Table 2.

Efficacy Outcomes.^*

Outcome	Milvexian Twice Daily				Milvexian Once Daily			Enoxaparin (N = 252)
	25 mg (N = 129)	50 mg (N = 124)	100 mg (N = 134)	200 mg (N = 131)	25 mg (N = 28)	50 mg (N = 127)	200 mg (N = 123)
Primary efficacy outcome: venous thromboembolism †
Any event — no. (%)	27 (21)	14 (11)	12 (9)	10 (8)	7 (25)	30 (24)	8 (7)	54 (21)
Relative risk vs. enoxaparin (95% CI)	0.97 (0.65–1.45)	0.53 (0.31–0.90)	0.42 (0.23–0.76)	0.37 (0.19–0.69)	1.00 (0.51–1.97)	1.15 (0.78–1.70)	0.30 (0.15–0.62)	—
Components of the primary efficacy outcome — no.‡
Death from any cause	0	0	0	0	0	0	0	1
Nonfatal pulmonary embolism	0	1	1	0	0	0	0	1
Symptomatic distal deep-vein thrombosis	0	0	1	0	0	2	0	0
Asymptomatic proximal deep-vein thrombosis	1	0	1	0	0	2	0	2
Asymptomatic distal deep-vein thrombosis	26	13	9	10	7	26	8	50
Extent of deep-vein thrombosis on venography — no.
Confluent distal into proximal	1	0	1	0	0	2	0	1
Isolated proximal
Large: ≥10 cm	0	0	0	0	0	0	0	0
Small: <10 cm	0	0	0	0	0	0	0	1
Isolated distal
Extensive: ≥2 veins	9	5	1	2	5	9	1	20
Limited: <2 veins	17	8	9	8	2	18	7	30

^*Efficacy outcomes were assessed in the modified intention-to-treat population, which included all the patients who had received at least one dose of a trial medication and had a venogram within the prespecified time window that could be evaluated, a documented symptomatic venous thromboembolic event, or a fatal event. CI denotes confidence interval.

^†Venous thromboembolism was a composite of asymptomatic deep-vein thrombosis (detected by mandatory unilateral venography performed 10 to 14 days after surgery), confirmed symptomatic venous thromboembolism (symptomatic deep-vein thrombosis of the leg or nonfatal pulmonary embolism), or death from any cause.

^‡There were no cases of symptomatic proximal deep-vein thrombosis.